BioLineRx (BLRX) Enters Exclusive License Agreement for BL-8020
Tweet
Share
E-mailGet Alerts BLRX Hot Sheet
Join SI Premium – FREE
BioLineRx (Nasdaq: BLRX) has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aggreko files for proposed IPO
- Interactive Brokers partners with Daol to serve Korean investors
- SCX.ai partners with DDN to expand Australian AI infrastructure
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
